Lipopolysaccharide: A tool and target in enterobacterial vaccine development

Gábor Nagy, Tibor Pál

Research output: Contribution to journalReview articlepeer-review

36 Citations (Scopus)


Lipopolysaccharide (LPS) is an essential component of Gram-negative bacteria. While mutants exhibiting truncated LPS molecules are usually over-attenuated, alternative approaches that affect the extent or timing of LPS expression, as well as its modification may establish the optimal balance for a live vaccine strain of sufficient attenuation and retained immunogenicity. On the other hand, a specific immune response to LPS molecules in itself is capable of conferring protective immunity to certain enterobacterial pathogens. Therefore, purified LPS derivatives could be used as parenteral vaccines. This review summarizes various LPS-based vaccination strategies, as well as approaches that utilize LPS mutants as whole-cell vaccines.

Original languageEnglish
Pages (from-to)513-520
Number of pages8
JournalBiological Chemistry
Issue number5
Publication statusPublished - May 1 2008
Externally publishedYes


  • Cross-protection
  • Escherichia coli
  • Multivalent vaccine
  • Salmonella
  • Shigella
  • Virulence attenuation

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Clinical Biochemistry


Dive into the research topics of 'Lipopolysaccharide: A tool and target in enterobacterial vaccine development'. Together they form a unique fingerprint.

Cite this